Literature DB >> 20958794

VWF and ADAMTS13 behavior in estradiol-treated HUVEC.

Yanina Powazniak1, Ana Catalina Kempfer, Julio César Calderazzo Pereyra, Juvenal Paiva Palomino, Maria Angela Lazzari.   

Abstract

OBJECTIVES: In this study, the role of 17β-estradiol (E2) in the regulation of von Willebrand factor (VWF) and ADAMTS13 synthesis, storage, and secretion was investigated in cultured human umbilical vein endothelial cells (HUVEC).
METHODS: HUVEC were grown to 80-90% confluence and replaced with fresh medium containing E2 (1 nm) or vehicle for 24 h, after which the supernatant medium and cell lysates were collected to measure VWF and ADAMTS13. VWF was evaluated by VWF:Ag and multimeric analysis. ADAMTS13 was evaluated by SDS-PAGE. VWF and ADAMTS13 mRNA were quantified by real-time PCR after E2 or vehicle exposure for 18 h. A functional effect of ADAMTS13 on HUVEC VWF protein synthesis was further evaluated using a short hairpin RNA (shRNA) to knockdown the expression of endogenous ADAMTS13.
RESULTS: E2 did not increase the release or intracellular VWF levels in HUVEC. However, E2 increased the production of intracellular ADAMTS13, although there was no evidence of significant effects of their release into culture medium. Incubation of HUVEC with E2 resulted in a significantly increased expression of VWF and ADAMTS13 mRNA. ADAMTS13 gene inactivation upregulates release and intracellular VWF levels in E2-treated HUVEC.
CONCLUSION: The results demonstrated that E2 may play a role in the regulation of VWF and ADAMTS13 gene expression and in its production in human endothelial cells. The mechanism of the protective effects of E2 on the cardiovascular system could be explained by the intracellular regulation of VWF produced by ADAMTS13.
© 2010 John Wiley & Sons A/S.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20958794     DOI: 10.1111/j.1600-0609.2010.01545.x

Source DB:  PubMed          Journal:  Eur J Haematol        ISSN: 0902-4441            Impact factor:   2.997


  4 in total

1.  Interaction between bone morphogenetic protein receptor type 2 and estrogenic compounds in pulmonary arterial hypertension.

Authors:  Joshua P Fessel; Xinping Chen; Andrea Frump; Santhi Gladson; Tom Blackwell; Christie Kang; Jennifer Johnson; James E Loyd; Anna Hemnes; Eric Austin; James West
Journal:  Pulm Circ       Date:  2013-12-02       Impact factor: 3.017

2.  Carriers of ADAMTS13 Rare Variants Are at High Risk of Life-Threatening COVID-19.

Authors:  Kristina Zguro; Margherita Baldassarri; Francesca Fava; Giada Beligni; Sergio Daga; Roberto Leoncini; Lucrezia Galasso; Michele Cirianni; Stefano Rusconi; Matteo Siano; Daniela Francisci; Elisabetta Schiaroli; Sauro Luchi; Giovanna Morelli; Enrico Martinelli; Massimo Girardis; Stefano Busani; Saverio Giuseppe Parisi; Sandro Panese; Carmelo Piscopo; Mario Capasso; Danilo Tacconi; Chiara Spertilli Raffaelli; Annarita Giliberti; Giulia Gori; Peter D Katsikis; Maria Lorubbio; Paola Calzoni; Agostino Ognibene; Monica Bocchia; Monica Tozzi; Alessandro Bucalossi; Giuseppe Marotta; Simone Furini; Alessandra Renieri; Chiara Fallerini
Journal:  Viruses       Date:  2022-05-29       Impact factor: 5.818

3.  MicroRNA-186-3p attenuates tumorigenesis of cervical cancer by targeting MCM2.

Authors:  Xiurong Lu; Xiao Song; Xiaohui Hao; Xiaoyu Liu; Xianyu Zhang; Na Yuan; Huan Ma; Zhilin Zhang
Journal:  Oncol Lett       Date:  2021-05-19       Impact factor: 2.967

4.  Phenotypic expression of ADAMTS13 in glomerular endothelial cells.

Authors:  Ramesh Tati; Ann-Charlotte Kristoffersson; Anne-Lie Ståhl; Matthias Mörgelin; David Motto; Simon Satchell; Peter Mathieson; Minola Manea-Hedström; Diana Karpman
Journal:  PLoS One       Date:  2011-06-24       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.